Cash down to $1.7m as $1.2m HY operating burn continues

Operating cash outflow narrowed to $1.2m from $1.7m (-29.3%), but the absolute drain remained sizeable against a $0.7m revenue base. Revenue was effectively unchanged at $0.74m, and the reported loss came in at $1.2m versus $1.3m, broadly similar in scale to HY22; we caveat specific growth percentages because the FY22 provision for impairment of non-current assets created a basis discontinuity in the prior comparable line.

Total equity fell to $2.3m from $9.7m and total assets to $2.9m from $10.3m, both reflecting that FY22 impairment. The balance sheet is now dominated by cash ($1.7m), inventory ($0.7m) and trade receivables ($0.15m versus $0.007m prior), with no gross borrowings.

With $1.7m of cash, an HY operating outflow of $1.2m, and revenue at $0.74m per half, the current cash balance supports roughly one to two more halves at the present burn rate without revenue acceleration, cost reduction, or a capital raise. For a sub-scale medical-diagnostics issuer, capital sufficiency is the dominant variable.

Revenue did not advance. Management framed HY revenue as "in line" and cited China COVID-Zero lockdowns. SUS unit sales were flat year-on-year, with device sales up modestly into China private health-check channels. The absence of unit and pricing leverage means operating losses are unlikely to narrow materially without a channel breakthrough.

Working capital is small in dollars but directional. Trade receivables rose from $7k to $150k, pushing receivable days from near zero to 37, and inventory days remained elevated near 174. In a sub-$1m revenue base, $0.15m of receivables and $0.7m of inventory tie up scarce cash relative to half-year sales.

The FY22 shape is not a clean seasonality guide: HY22 carried 44.4% of FY22 revenue but only 16% of FY22 NPAT, and that asymmetry sits in the FY22 impairment booked in the second half rather than a recurring 2H business pattern. On revenue alone, an annualised run-rate of approximately $1.5m sits below FY22 product revenue of $1.7m, so matching last year would require a stronger second half.

Management commentary cites China lockdown disruption and continued expansion in private health-check channels but provides no quantified outlook against which this half can be judged.

Cash burn of $1.2m against revenue of $0.74m means the business remains a cash-consuming, development-stage device operation rather than a self-funding commercial one. We avoid framing the revenue and loss changes as percentage trends because the FY22 impairment created a basis discontinuity that the company itself disclosed.

The collapse in total equity (-76.1%) and total assets (-71.6%) versus HY22 is not an HY23 operating event; it carries forward the FY22 impairment of remaining non-current assets. The HY23 balance sheet is now an essentially cash-and-working-capital structure with no borrowings, which is a cleaner but smaller base from which to scale. The most durable feature of the result is the absence of debt; the least durable is the dependence on a $1.7m cash buffer to fund continuing losses.

This briefing cannot assess management's specific cash runway forecast or capital plan because no quantified outlook or funding guidance was disclosed.